TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Expression of Erdr1 cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of device related adverse events at moment of stent placement
Endpoint domain: Adverse events/effects
Primary endpoint: Safety profile of Butyricicoccus pullicaecorum intake
Endpoint domain: Adverse events/effects
Primary endpoint: number of embryos appropriate for transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: anterograde episodic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: retrograde episodic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decompressive changes in CT brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Volume of breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of the computer-aided system for predicting polyps histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non progression rate in brain metastases
Endpoint domain: Mortality/survival
Primary endpoint: Incidence and severity of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum hormone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Follicle development and ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pregnancy and miscarriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in empyema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in functional score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Biliary stricture resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Functional CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of Drug in Tumor Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Perceived Stress Scale (PSS-10) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ultrasonographic Muscle Size Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in [18F]-5-Fluorouracil tumor uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in perceived emotional intelligence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score on an ability measure of emotional intelligence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Disease-control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Polysomnography parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety profile during procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in nasal symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Albumin Excretion Decrease of 20% or More
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of Prescribed Glaucoma Medication Doses Taken on Schedule
Endpoint domain: Life impact
Endpoint subdomain: Adherence to treatment
Primary endpoint: Change in the excess of volume of upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graded changes in blood flow and oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cytokine levels (IFN-gamma, IL-10, TNF-alpha, TGF-beta)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Protective effect against sunburn response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in parameters of platelet activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in parameter for platelet oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in parameter for platelet oxidation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum Thromboxane measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportions of regulatory immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Optimal balloon volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-Drain Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rivermead Post-Concussion Symptoms Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change of plasma SIRT-1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change of plasma sclerostin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change of plasma FGF-23 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change of plasma IL-6 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change of plasma total calcium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change of plasma phosphate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of Melanin index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of erythema index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ocular concentration of Erythropoietin and VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tigecycline Steady State Plasma Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI signal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gracely Scale pain rating changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resting state functional connectivity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall Disease Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of acute respiratory illnesses with specimen available for testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in TETRAS Spiral Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean values of facial profile angles and linear measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolomic signatures for diagnosing OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in metabolomic signatures with PAP treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of postmenopausal women with D inadequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-social (Monetary) Reward Response (Reward Learning and Sensitivity)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Non-social (Monetary) Reward Response (Reward Motivation)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: General Social Reward Response (Social Reward Motivation)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Severe TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: locoregionally control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Free From Major Adverse Events (MAEs) at 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Primary Patency of Stented Segment at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in metabolic syndrome risk component
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recovery status of patients after surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Composite Assessment of Function and Survival (CAFS) at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death up to 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in ALSFRS-R at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24hr Urinary Sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24hr Urinary Dopamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cosmetic scar appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cusp surface areas over the cardiac cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cusp height (geometric and effective)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cusp thickness (including raphe thickness, if applicable)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time until discharge from PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Response (Complete or Partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from documented atrial tachyarrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CSF Brain Derived Neurotrophic Factor (BDNF) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of newborns with major congenital malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of pregnancy outcomes with major congenital malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Satisfaction with contraception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Successful IV cannulation on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in capillary recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aspirin Reaction Units (ARU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ongoing pregnancy rate at 12 weeks gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Presence of specific findings associated with Fabry's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Whom Had Proper Preparation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: in-stent late loss at 9M
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional status measured by Karnofsky performance scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Foot Functional Index revised short version (FFI-RS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of women who will be ovulated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants With Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of central access device patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Growth Factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma pharmacokinetics of docetaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Response of the Marker Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Differences in gut microbiome profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of blood biomarkers with gut microbiome taxa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric muscle twitch force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in immunosuppressive markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Viral Load Measurement <200 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Ovulation Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ovulatory dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence, Nature, and Severity of Treatment Emergent Adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Hippocampal Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of BMI percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Expression level of markers associated with IBD activity or prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to GVHD treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Distance Between Dural Sac Termination Level And Placement Of Caudal Epidural Needle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Caudal Epidural Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal Death
Endpoint domain: Mortality/survival
Primary endpoint: Inter-Rater Agreement on the Physician Assessed Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in the body image
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number and duration of right ventricular outflow tract arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grade 3 pulmonary graft dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Radiologic Evidence of Bone Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Net Change of the Urinary Distress Inventory (UDI-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Net Change of the Incontinence Impact Questionnaire (IIQ-7)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Net Change of the Quality of Life Index (QoL-I)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hypoglycemic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma insulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Subjective dizziness and vestibular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective vestibular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in corneal transparency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Gambling Frequency
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes in Problem Gambling Severity Index (PGSI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Kessler-6 (K6)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of whole brain atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RP Attacks Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain reporting accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in experimental pain perception due to placebo pill intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant's Physiological Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C max,ss of Udenafil and Bosentan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC tau,ss of Udenafil and Bosentan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time delay from ictus to hospital arrival
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Relapse-related Events Normalized to Unit Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of post surgery hospitalisation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Differences in tumor morphology and molecular features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stratification of estrogen receptor-positive breast cancer into prognostic categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of new therapeutic targets in the PI3-kinase signaling pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Photosensitivity response suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression-free Survival (PFS) - Number of Participants With Progression or Death
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free Survival (PFS) - Median PFS
Endpoint domain: Mortality/survival
Primary endpoint: Survival at Day+100 Following Hematopoietic Stem Cell Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Complete Response by Day+100 Post Hematopoietic Stem Cell Transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip Strength Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flare up to Week 40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of Bisthianostat
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-related adverse events considered as dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance Measurement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lequesne Functional Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement Percentage of Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of new admissions to emergency rooms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients with sentinel lymph nodes in the parametrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Time to Disability Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain carnosine change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Continuous Glucose Monitoring (CGM)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sustained virological response 12 weeks after treatment (SVR-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmissions to emergency department
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total Radioactivity in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Radioactivity in Feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Angiotensin II stimulated S-aldosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Subjects Experiencing a Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Cognitive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum tolerated combination (MTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vedolizumab concentrations in stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with confirmed MR4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of death and major stroke
Endpoint domain: Mortality/survival
Primary endpoint: Area under the effect (IGF-I) curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of women who received an IUD or implant
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention